PL3802608T3 - Przeciwciała anty-cd3 i ich zastosowania - Google Patents

Przeciwciała anty-cd3 i ich zastosowania

Info

Publication number: PL3802608T3
Authority: PL; Poland
Prior art keywords: antibodies
Prior art date: 2018-05-24

Application number

PL19737219.6T

Other languages

English (en)

Inventor

Francois Gaudet

Jill Giles-Komar

Bradley Heidrich

Chichi Huang

Colleen Kane

Ronan MCDAID

Jennifer NEMETH-SEAY

Original Assignee

Janssen Biotech, Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-05-24

Filing date

2019-05-21

Publication date

2025-07-28

2019-05-21 Application filed by Janssen Biotech, Inc filed Critical Janssen Biotech, Inc

2025-07-28 Publication of PL3802608T3 publication Critical patent/PL3802608T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Cell Biology (AREA)
Reproductive Health (AREA)
Pregnancy & Childbirth (AREA)
Gynecology & Obstetrics (AREA)
Oncology (AREA)
Hematology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL19737219.6T 2018-05-24 2019-05-21 Przeciwciała anty-cd3 i ich zastosowania PL3802608T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201862676081P	2018-05-24	2018-05-24
PCT/IB2019/054188 WO2019224717A2 (en)	2018-05-24	2019-05-21	Anti-cd3 antibodies and uses thereof

Publications (1)

Publication Number	Publication Date
PL3802608T3 true PL3802608T3 (pl)	2025-07-28

Family

ID=67211773

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL19737219.6T PL3802608T3 (pl)	2018-05-24	2019-05-21	Przeciwciała anty-cd3 i ich zastosowania

Country Status (38)

Country	Link
US (2)	US11603405B2 (pl)
EP (2)	EP4643951A3 (pl)
JP (2)	JP7530299B2 (pl)
KR (1)	KR20210012007A (pl)
CN (2)	CN120058941A (pl)
AR (1)	AR115422A1 (pl)
AU (1)	AU2019274656B2 (pl)
BR (1)	BR112020023508A2 (pl)
CA (1)	CA3101271A1 (pl)
CL (1)	CL2020003033A1 (pl)
CO (1)	CO2020014506A2 (pl)
CR (1)	CR20200568A (pl)
DK (1)	DK3802608T3 (pl)
EA (1)	EA202092847A1 (pl)
EC (1)	ECSP20075215A (pl)
ES (1)	ES3032856T3 (pl)
FI (1)	FI3802608T3 (pl)
HR (1)	HRP20250621T1 (pl)
HU (1)	HUE072251T2 (pl)
IL (1)	IL278846A (pl)
JO (1)	JOP20200302A1 (pl)
LT (1)	LT3802608T (pl)
MA (1)	MA52773B1 (pl)
MX (1)	MX420253B (pl)
NI (1)	NI202000089A (pl)
PE (1)	PE20210132A1 (pl)
PH (1)	PH12020551920A1 (pl)
PL (1)	PL3802608T3 (pl)
PT (1)	PT3802608T (pl)
RS (1)	RS66901B1 (pl)
SA (1)	SA520420631B1 (pl)
SG (1)	SG11202011270QA (pl)
SI (1)	SI3802608T1 (pl)
SM (1)	SMT202500221T1 (pl)
TW (1)	TW202012443A (pl)
UA (1)	UA129050C2 (pl)
UY (1)	UY38245A (pl)
WO (1)	WO2019224717A2 (pl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL319047A (en)	2015-08-28	2025-04-01	Amunix Operating Inc	Chimeric polypeptide composition and methods for its preparation and use
WO2018119142A1 (en)	2016-12-21	2018-06-28	Amgen Inc.	Anti-tnf alpha antibody formulations
CA3066918A1 (en)	2017-06-12	2018-12-20	Bluefin Biomedicine, Inc.	Anti-il1rap antibodies and antibody drug conjugates
SG11202011633SA (en)	2018-05-24	2020-12-30	Janssen Biotech Inc	Psma binding agents and uses thereof
MA52772A (fr)	2018-05-24	2021-04-14	Janssen Biotech Inc	Anticorps anti-tmeff2 monospécifiques et multispécifiques et leurs utilisations
JOP20190116A1 (ar) *	2018-05-24	2019-11-24	Janssen Biotech Inc	الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
TWI838389B (zh)	2018-07-19	2024-04-11	美商再生元醫藥公司	雙特異性抗-BCMAｘ抗-CD3抗體及其用途
MD4324851T2 (ro)	2018-07-19	2025-12-31	Regeneron Pharma	Receptori antigenici chimerici cu specificitate BCMA și utilizările acestora
BR112021020532A2 (pt)	2019-04-19	2022-03-15	Janssen Biotech Inc	Métodos para tratamento de câncer de próstata com um anticorpo anti-psma/cd3
KR20220040483A (ko)	2019-07-26	2022-03-30	얀센 바이오테크 인코포레이티드	칼리크레인 관련 펩티다제 2 항원 결합 도메인을 포함하는 단백질 및 이의 용도
CA3164972A1 (en) *	2019-12-18	2021-06-24	Janssen Biotech, Inc.	Materials and methods for in vivo biological targeting
KR20220147631A (ko) *	2020-02-27	2022-11-03	얀센 바이오테크 인코포레이티드	면역 반응을 조절하기 위한 물질 및 방법
US20210284731A1 (en) *	2020-03-13	2021-09-16	Janssen Biotech, Inc.	Methods and materials for modulating an immune response
CN116249714A (zh)	2020-05-27	2023-06-09	詹森生物科技公司	包含cd3抗原结合结构域的蛋白质及其用途
JP2023536818A (ja)	2020-07-29	2023-08-30	ヤンセンバイオテツク，インコーポレーテツド	Ｈｌａ－ｇ抗原結合ドメインを含むタンパク質及びそれらの使用
CN116472060A (zh) *	2020-09-02	2023-07-21	健玛保	抗体疗法
EP4214233A1 (en)	2020-09-16	2023-07-26	Amgen Inc.	Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
KR20230079409A (ko) *	2020-09-29	2023-06-07	이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드	항-cd3 항체 및 이의 용도
TW202233672A (zh)	2020-10-22	2022-09-01	美商健生生物科技公司	包括類δ配體３（ＤＬＬ３）抗原結合區之蛋白質及其用途
IL305144A (en) *	2021-02-16	2023-10-01	Janssen Pharmaceutica Nv	Trispecific antibodies targeting BCMA, GPRC5D and CD3
JP2024520338A (ja)	2021-05-21	2024-05-24	レオファーマアクティーゼルスカブ	抗ｉｌ－１受容体アクセサリータンパク質抗体
MX2024002476A (es) *	2021-08-27	2024-05-20	Janssen Biotech Inc	Anticuerpos anti-psma y usos de estos.
US12600764B2 (en) *	2021-08-27	2026-04-14	International Business Machines Corporation	Antigen-binding proteins targeting coronavirus (COV) variants
JP2025510266A (ja) *	2022-03-25	2025-04-14	嘉和生物▲薬▼▲業▼有限公司	Ｃｄ３を標的とする抗体及びその使用
AU2023345467A1 (en) *	2022-09-21	2025-05-08	Sanofi Biotechnology	Humanized anti-il-1r3 antibody and methods of use
EP4598958A1 (en)	2022-10-05	2025-08-13	Amgen Inc.	Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
WO2024089551A1 (en)	2022-10-25	2024-05-02	Janssen Biotech, Inc.	Msln and cd3 binding agents and methods of use thereof
WO2024126833A1 (en) *	2022-12-16	2024-06-20	Ichnos Sciences SA	Cd47-il1rap bispecific antibodies
WO2025134050A1 (en)	2023-12-21	2025-06-26	Janssen Biotech, Inc	Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of multiple myeloma
WO2025134049A1 (en)	2023-12-21	2025-06-26	Janssen Biotech, Inc	Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis
TW202602940A (zh)	2024-04-09	2026-01-16	美商安進公司	激動性抗ｉｌ－２ｒｂｇ重鏈抗體
WO2025230233A1 (ko) *	2024-05-03	2025-11-06	국민대학교산학협력단	인간 cd3에 특이적인 항체 및 이의 용도
WO2026006495A1 (en)	2024-06-25	2026-01-02	Alloy Therapeutics, Inc.	Anti-wt1/hla-a2 antibody and uses thereof
WO2026006492A2 (en)	2024-06-25	2026-01-02	Ypsilon Therapeutics, Inc.	Anti-prame/hla-a2 antibodies and uses thereof
WO2026078647A1 (en)	2024-10-11	2026-04-16	Janssen Biotech, Inc.	Combination of trispecific antibody targeting bcma, gprc5d and cd3, and pomalidomide for the treatment of multiple myeloma
WO2026078659A1 (en)	2024-10-11	2026-04-16	Janssen Biotech, Inc.	Combination of trispecific antibody targeting bcma, gprc5d and cd3, and an anti-cd38 antibody for the treatment of multiple myeloma

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
ATE87659T1 (de)	1986-09-02	1993-04-15	Enzon Lab Inc	Bindungsmolekuele mit einzelpolypeptidkette.
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US6172197B1 (en)	1991-07-10	2001-01-09	Medical Research Council	Methods for producing members of specific binding pairs
US6255458B1 (en)	1990-08-29	2001-07-03	Genpharm International	High affinity human antibodies and human antibodies against digoxin
EP1400536A1 (en)	1991-06-14	2004-03-24	Genentech Inc.	Method for making humanized antibodies
ES2341666T3 (es)	1991-12-02	2010-06-24	Medimmune Limited	Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
ATE199392T1 (de)	1992-12-04	2001-03-15	Medical Res Council	Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en)	1997-03-27	1997-04-24	Commonwealth Scientific And Industrial Research Organisation	High avidity polyvalent and polyspecific reagents
US6670127B2 (en)	1997-09-16	2003-12-30	Egea Biosciences, Inc.	Method for assembly of a polynucleotide encoding a target polypeptide
PT1538206E (pt)	1997-09-16	2010-04-12	Centocor Ortho Biotech Inc	Método para a síntese química e construção completa de genes e genomas
US6818749B1 (en)	1998-10-31	2004-11-16	The United States Of America As Represented By The Department Of Health And Human Services	Variants of humanized anti carcinoma monoclonal antibody cc49
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
CN1487996B (zh)	2000-11-30	2010-06-16	米德列斯公司	用于生产人类抗体的转基因转染色体啮齿动物
MXPA05000511A (es)	2001-07-12	2005-09-30	Jefferson Foote	Anticuepros super humanizados.
EP1789446A2 (en)	2004-09-02	2007-05-30	Genentech, Inc.	Heteromultimeric molecules
EP3050963B1 (en)	2005-03-31	2019-09-18	Chugai Seiyaku Kabushiki Kaisha	Process for production of polypeptide by regulation of assembly
DE102005028778A1 (de)	2005-06-22	2006-12-28	SUNJÜT Deutschland GmbH	Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
US8871912B2 (en)	2006-03-24	2014-10-28	Merck Patent Gmbh	Engineered heterodimeric protein domains
WO2007147901A1 (en)	2006-06-22	2007-12-27	Novo Nordisk A/S	Production of bispecific antibodies
KR20100058509A (ko)	2007-07-31	2010-06-03	메디뮨 엘엘씨	다중특이적 에피토프 결합 단백질 및 이의 용도
US8748356B2 (en)	2007-10-19	2014-06-10	Janssen Biotech, Inc.	Methods for use in human-adapting monoclonal antibodies
JP2011507519A (ja)	2007-12-19	2011-03-10	セントコア・オーソ・バイオテツク・インコーポレーテツド	ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
US8242247B2 (en)	2007-12-21	2012-08-14	Hoffmann-La Roche Inc.	Bivalent, bispecific antibodies
US9266967B2 (en)	2007-12-21	2016-02-23	Hoffmann-La Roche, Inc.	Bivalent, bispecific antibodies
US8227577B2 (en)	2007-12-21	2012-07-24	Hoffman-La Roche Inc.	Bivalent, bispecific antibodies
US20090162359A1 (en)	2007-12-21	2009-06-25	Christian Klein	Bivalent, bispecific antibodies
JP2012505654A (ja)	2008-10-14	2012-03-08	ヤンセンバイオテツク，インコーポレーテツド	抗体をヒト化及び親和性成熟する方法
JP2012525149A (ja)	2009-04-27	2012-10-22	オンコメッドファーマシューティカルズインコーポレイテッド	ヘテロ多量体分子を作製するための方法
DK2560993T3 (da)	2010-04-20	2024-10-14	Genmab As	Heterodimeric antibody fc-containing proteins and methods for production thereof
PL2635607T3 (pl)	2010-11-05	2020-05-18	Zymeworks Inc.	Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
DK2714733T3 (da)	2011-05-21	2019-05-06	Macrogenics Inc	Cd3-bindende molekyler, der er i stand til at binde til human og ikke-human cd3
CA2854233C (en)	2011-11-04	2020-05-12	Zymeworks Inc.	Stable heterodimeric antibody design with mutations in the fc domain
JOP20200236A1 (ar)	2012-09-21	2017-06-16	Regeneron Pharma	الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
HRP20231356T1 (hr)	2012-12-14	2024-02-16	Omniab, Inc.	Polinukleotidi koji kodiraju protutijela glodavaca s ljudskim idiotipovima i životinje koje ih sadrže
MX373245B (es) *	2013-07-05	2020-05-11	Genmab As	Anticuerpos cd3 humanizados o quiméricos.
UA129760C2 (uk)	2013-12-17	2025-07-30	Дженентек, Інк.	Анти-cd3 антитіло та спосіб його застосування
CA2942453A1 (en) *	2014-05-28	2015-12-03	F. Hoffmann-La Roche Ag	Antibodies binding to human and cynomolgus cd3 epsilon
EP2982693A1 (en) *	2014-08-07	2016-02-10	Affimed Therapeutics AG	CD3 binding domain
CR20170383A (es) *	2015-01-23	2017-11-22	Sanofi Sa	Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
AU2016350705A1 (en)	2015-11-02	2018-05-17	Janssen Pharmaceutica Nv	Anti-IL1RAP antibodies, bispecific antigen binding molecules that bind IL1RAP and CD3, and uses thereof
FI4050034T3 (fi)	2016-09-14	2024-06-10	Teneoone Inc	Cd3:een sitoutuvia vasta-aineita
US12012461B2 (en) *	2018-05-16	2024-06-18	Janssen Biotech, Inc.	Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics
JOP20190116A1 (ar)	2018-05-24	2019-11-24	Janssen Biotech Inc	الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
SG11202011633SA (en)	2018-05-24	2020-12-30	Janssen Biotech Inc	Psma binding agents and uses thereof
MA52772A (fr)	2018-05-24	2021-04-14	Janssen Biotech Inc	Anticorps anti-tmeff2 monospécifiques et multispécifiques et leurs utilisations

2019
- 2019-05-21 US US16/418,082 patent/US11603405B2/en active Active
- 2019-05-21 CN CN202510209510.8A patent/CN120058941A/zh active Pending
- 2019-05-21 ES ES19737219T patent/ES3032856T3/es active Active
- 2019-05-21 SI SI201930938T patent/SI3802608T1/sl unknown
- 2019-05-21 MX MX2020012587A patent/MX420253B/es unknown
- 2019-05-21 JO JOP/2020/0302A patent/JOP20200302A1/ar unknown
- 2019-05-21 FI FIEP19737219.6T patent/FI3802608T3/fi active
- 2019-05-21 EA EA202092847A patent/EA202092847A1/ru unknown
- 2019-05-21 UA UAA202008271A patent/UA129050C2/uk unknown
- 2019-05-21 HU HUE19737219A patent/HUE072251T2/hu unknown
- 2019-05-21 RS RS20250579A patent/RS66901B1/sr unknown
- 2019-05-21 AU AU2019274656A patent/AU2019274656B2/en active Active
- 2019-05-21 PE PE2020001886A patent/PE20210132A1/es unknown
- 2019-05-21 BR BR112020023508-3A patent/BR112020023508A2/pt unknown
- 2019-05-21 PT PT197372196T patent/PT3802608T/pt unknown
- 2019-05-21 CR CR20200568A patent/CR20200568A/es unknown
- 2019-05-21 WO PCT/IB2019/054188 patent/WO2019224717A2/en not_active Ceased
- 2019-05-21 SM SM20250221T patent/SMT202500221T1/it unknown
- 2019-05-21 PL PL19737219.6T patent/PL3802608T3/pl unknown
- 2019-05-21 CA CA3101271A patent/CA3101271A1/en active Pending
- 2019-05-21 LT LTEPPCT/IB2019/054188T patent/LT3802608T/lt unknown
- 2019-05-21 EP EP25173398.6A patent/EP4643951A3/en active Pending
- 2019-05-21 MA MA52773A patent/MA52773B1/fr unknown
- 2019-05-21 JP JP2020565282A patent/JP7530299B2/ja active Active
- 2019-05-21 SG SG11202011270QA patent/SG11202011270QA/en unknown
- 2019-05-21 HR HRP20250621TT patent/HRP20250621T1/hr unknown
- 2019-05-21 EP EP19737219.6A patent/EP3802608B1/en active Active
- 2019-05-21 KR KR1020207037046A patent/KR20210012007A/ko active Pending
- 2019-05-21 DK DK19737219.6T patent/DK3802608T3/da active
- 2019-05-21 CN CN201980049271.7A patent/CN112912397B/zh active Active
- 2019-05-24 TW TW108118086A patent/TW202012443A/zh unknown
- 2019-05-24 UY UY0001038245A patent/UY38245A/es unknown
- 2019-05-24 AR ARP190101400A patent/AR115422A1/es unknown
2020
- 2020-11-09 PH PH12020551920A patent/PH12020551920A1/en unknown
- 2020-11-19 IL IL278846A patent/IL278846A/en unknown
- 2020-11-23 EC ECSENADI202075215A patent/ECSP20075215A/es unknown
- 2020-11-23 NI NI202000089A patent/NI202000089A/es unknown
- 2020-11-23 CO CONC2020/0014506A patent/CO2020014506A2/es unknown
- 2020-11-23 CL CL2020003033A patent/CL2020003033A1/es unknown
- 2020-11-24 SA SA520420631A patent/SA520420631B1/ar unknown
2023
- 2023-03-08 US US18/180,225 patent/US20230322924A1/en active Granted
2024
- 2024-05-29 JP JP2024087232A patent/JP2024116190A/ja active Pending

Also Published As

Publication number	Publication date
PH12020551920A1 (en)	2021-06-14
EP3802608B1 (en)	2025-04-30
ES3032856T3 (en)	2025-07-28
ECSP20075215A (es)	2020-12-31
DK3802608T3 (da)	2025-06-10
KR20210012007A (ko)	2021-02-02
MX420253B (es)	2025-02-10
EA202092847A1 (ru)	2021-04-20
JOP20200302A1 (ar)	2020-11-23
CR20200568A (es)	2021-02-26
SA520420631B1 (ar)	2023-12-03
JP2024116190A (ja)	2024-08-27
US20200048349A1 (en)	2020-02-13
MX2020012587A (es)	2021-04-28
CA3101271A1 (en)	2019-11-28
EP4643951A2 (en)	2025-11-05
SMT202500221T1 (it)	2025-07-22
EP3802608A2 (en)	2021-04-14
NI202000089A (es)	2021-01-21
CN112912397A (zh)	2021-06-04
SI3802608T1 (sl)	2025-08-29
PT3802608T (pt)	2025-06-27
AR115422A1 (es)	2021-01-20
SG11202011270QA (en)	2020-12-30
HRP20250621T1 (hr)	2025-07-18
RS66901B1 (sr)	2025-07-31
WO2019224717A3 (en)	2020-03-05
US11603405B2 (en)	2023-03-14
PE20210132A1 (es)	2021-01-19
CN120058941A (zh)	2025-05-30
WO2019224717A9 (en)	2021-02-04
CO2020014506A2 (es)	2020-12-10
UA129050C2 (uk)	2025-01-01
TW202012443A (zh)	2020-04-01
IL278846A (en)	2021-01-31
LT3802608T (lt)	2025-06-25
AU2019274656B2 (en)	2026-03-19
FI3802608T3 (fi)	2025-06-11
WO2019224717A2 (en)	2019-11-28
JP2021524249A (ja)	2021-09-13
US20230322924A1 (en)	2023-10-12
AU2019274656A1 (en)	2020-11-26
EP4643951A8 (en)	2025-12-10
JP7530299B2 (ja)	2024-08-07
CN112912397B (zh)	2025-03-14
MA52773B1 (fr)	2025-05-30
MA52773A (fr)	2021-04-14
BR112020023508A2 (pt)	2021-03-30
UY38245A (es)	2019-11-29
CL2020003033A1 (es)	2021-04-16
HUE072251T2 (hu)	2025-11-28
EP4643951A3 (en)	2026-01-14

Publication	Publication Date	Title
IL278846A (en)	2021-01-31	Anti-CD3 antibodies and uses thereof
HUS2500032I1 (hu)	2025-09-28	Bispecifikus anti-BCMA X anti-CD3 antitestek és azok alkalmazásai
IL282968A (en)	2021-06-30	Anti-NKG2A antibodies and their use
IL276950A (en)	2020-10-29	Anti-CD73 antibodies and uses thereof
SG11202105885WA (en)	2021-07-29	Anti-claudin antibodies and uses thereof
ZA202006066B (en)	2021-09-29	Anti-hla-g antibodies and use thereof
IL275826A (en)	2020-08-31	Anti-mct1 antibodies and their uses
IL275734B (en)	2022-06-01	Anti-pd-l1 antibodies and uses thereof
IL278466B1 (en)	2026-04-01	Anti-dll3 antibodies and uses thereof
IL280321A (en)	2021-03-01	Antibodies against CXCR2 and their uses
IL281202A (en)	2021-04-29	Anti-TNFRSF9 antibodies and uses thereof
ZA202100714B (en)	2023-07-26	Anti-npr1 antibodies and uses thereof
IL282707A (en)	2021-06-30	Anti-tim-3 antibodies and their use
IL277075A (en)	2020-10-29	Anti-PHF-tau antibodies and uses thereof
SG11202009625WA (en)	2020-10-29	Anti-trem-1 antibodies and uses thereof
SG11202105161YA (en)	2021-06-29	Anti-il-27 antibodies and uses thereof
IL282708A (en)	2021-06-30	Anti-tim-3 antibodies and their use
IL277330A (en)	2020-10-29	Anti-IL-27 antibodies and uses thereof
IL276548A (en)	2020-09-30	Binding antibodies - BCMA and their uses
SG11202012680TA (en)	2021-01-28	Anti-l1cam antibodies and uses thereof
IL283890A (en)	2021-07-29	Anti-periostin antibodies and their uses
GB201820334D0 (en)	2019-01-30	Antibodies and their uses